- Conditions
- Medication Absorption
- Interventions
- Water, Parmalat™ Whole Milk, Similac Pro-Advance™, Ensure Plus™, Furosemide 20 MG
- Dietary Supplement · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 40 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–23
of 23
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy
- Interventions
- Potassium Supplement, Furosemide 20 MG, Compression Garment
- Drug · Device
- Lead sponsor
- National Aeronautics and Space Administration (NASA)
- Federal
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Heart Failure, Congestive
- Interventions
- Furosemide, Torsemide, Bumetanide, sacubitril/valsartan, Hydralazine, Isosorbide Dinitrate
- Drug
- Lead sponsor
- Heart Center Research, LLC
- Network
- Eligibility
- 19 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Huntsville, Alabama
- Conditions
- Schizophrenia
- Interventions
- furosemide, Na supplements
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
- Interventions
- Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
- Other · Drug
- Lead sponsor
- University Health Network, Toronto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Hypertension (HTN)
- Interventions
- Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Fluid Overload, Heart Failure Acute
- Interventions
- Metolazone 60 minutes prior to furosemide, Metolazone concurrently with furosemide
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Heart Failure, Heart Failure Acute, Acute Cardiac Pulmonary Edema, Acute Cardiac Failure
- Interventions
- LUS-guided strategy-of-care, Usual Care, Intravenous Loop Diuretic, Vasodilator, Non invasive Ventilation (NIV)
- Other · Drug · Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Detroit, Michigan • Cleveland, Ohio + 2 more
- Conditions
- Congestive Heart Failure
- Interventions
- SLV320
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- Whittier, California • Largo, Florida • Miami, Florida + 7 more
- Conditions
- Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
- Interventions
- Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture
- Biological · Drug · Procedure + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Minneapolis, Minnesota
- Conditions
- Hematological Malignancy
- Interventions
- Cohort 1-Bortezomib (Velcade ®), Cohort 2-Bortezomib (Velcade ®), Cohort 3-Bortezomib (Velcade ®)
- Drug
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia, Hypertension, Pregnancy-Induced, Hypertension
- Interventions
- Furosemide, Placebo
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
- Interventions
- Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Heart Failure
- Interventions
- Conivaptan, Furosemide, Conivaptan and furosemide
- Drug
- Lead sponsor
- Hennepin County Medical Center, Minneapolis
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Chronic Kidney Disease
- Interventions
- Furosemide, Placebo
- Drug · Other
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Hypertension, Pregnancy-Induced
- Interventions
- Oral furosemide, Placebo Oral Tablet
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, Type 1 Diabetes (T1D)
- Interventions
- Kidney Biopsy, MRI, Retina Scan
- Procedure · Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 9 more
- Conditions
- AML
- Interventions
- Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only), Spironolactone
- Drug · Biological
- Lead sponsor
- Actinium Pharmaceuticals
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Lexington, Kentucky • Louisville, Kentucky + 10 more
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
- Interventions
- Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 40 Years to 79 Years
- Enrollment
- 10,251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 6
- States / cities
- Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
- Conditions
- Hypertension
- Interventions
- Furosemide, Potassium chloride, Placebo #1, Placebo #2
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • St Louis, Missouri
- Conditions
- Diabetic Nephropathy
- Interventions
- Addition of furosemide 20 mg oral bid to baseline regimen
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 2
- States / cities
- Santa Clara, California • Stanford, California
- Conditions
- Heart Failure, Heart Failure Acute, Acute Cardiac Failure, Acute Cardiac Pulmonary Edema
- Interventions
- Nitrates, Loop Diuretics
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Nashville, Tennessee
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- High-dose furosemide, Low-dose furosemide, Low-dose furosemide combined with low-dose dopamine
- Drug
- Lead sponsor
- Larissa University Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Cleveland, Ohio